The largest pharmacy-benefit managers hiked the prices of certain drugs dispensed through their own pharmacies, according to ...
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...
A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.